Plain-English translation of NCT06770296 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Breast Cancer research guide โPhase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This study is testing a medication called pyrotinib to find the best dose when combined with two standard breast cancer drugs (trastuzumab and paclitaxel) for people with advanced HER2-positive breast cancer. About 200 patients will be randomly assigned to take either a lower or higher dose of this medication. The goal is to determine which dose works most safely and effectively as a first-line treatment.
HER2-positive breast cancer is an aggressive form of the disease, and while existing treatments help, doctors want to find better combinations and doses that improve outcomes. This trial will help determine the optimal dose of this newer medication to maximize benefits while minimizing side effects.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you enroll, you will randomly receive either the lower or higher dose of the new medication, taken by mouth once daily in 3-week cycles, along with two standard chemotherapy drugs given intravenously. You will have regular clinic visits and blood tests to monitor how you're responding and check for side effects. The study runs from late 2024 through late 2026, and your participation will involve ongoing treatment visits and imaging scans to measure how well the cancer is responding.
AI-generated summary from trial data ยท Jun 30, 2026 ยท Not medical advice
China